Changzhou To Build RMB 520 Million Biotech Business Incubator
This article was originally published in PharmAsia News
Changzhou Fangyuan Pharmaceutical held a foundation-laying and signing ceremony for a biomedical incubator project Jan. 16, which was attended by Changzhou Ji-Mei Biotech and other companies
You may also be interested in...
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.